

Article

Resting-State Isolated Effective Connectivity of the Cingulate Cortex as a Neurophysiological Biomarker in Patients with Severe Treatment-Resistant Schizophrenia

Masataka Wada ¹, Shinichiro Nakajima ^{1,*}, Ryosuke Tarumi ^{1,2}, Fumi Masuda ¹, Takahiro Miyazaki ¹, Sakiko Tsugawa ¹, Kamiyu Ogyu ¹, Shiori Honda ³, Karin Matsushita ⁴, Yudai Kikuchi ⁴, Shinya Fujii ⁴, Daniel M. Blumberger ⁵, Zafiris J. Daskalakis ⁵, Masaru Mimura ¹ and Yoshihiro Noda ^{1,*} 

¹ Department of Neuropsychiatry, Keio University School of Medicine, Tokyo 160-8582, Japan; m.wada@keio.jp (M.W.); ryosuke1114@gmail.com (R.T.); fumi_masuda@keio.jp (F.M.); takahime.miyazaki@nifty.com (T.M.); sakiko.tsugawa@gmail.com (S.T.); camille.1896@gmail.com (K.O.); mimura@a7.keio.jp (M.M.)

² Department of Psychiatry, Komagino Hospital, Tokyo 193-8505, Japan

³ Graduate School of Media and Governance, Keio University, Kanagawa, Tokyo 252-0882, Japan; shiori.0913.honda@keio.jp

⁴ Faculty of Environment and Information Studies, Keio University, Kanagawa, Tokyo 252-0882, Japan; t17752km@sfc.keio.ac.jp (K.M.); yudai-kikuchi@keio.jp (Y.K.); fujii.shinya@gmail.com (S.F.)

⁵ Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, ON M6J 1H4, Canada; Daniel.Blumberger@camh.ca (D.M.B.); Jeff.Daskalakis@camh.ca (Z.J.D.)

* Correspondence: shinichiro_nakajima@hotmail.com (S.N.); yoshi-tms@keio.jp (Y.N.); Tel.: +81-3-3353-1211 (ext. 62454) (S.N.); +81-3-3353-1211 (ext. 61857) (Y.N.); Fax: +81-3-5379-0187 (S.N. & Y.N.)

Received: 21 June 2020; Accepted: 12 August 2020; Published: 14 August 2020



Abstract: Background: The neural basis of treatment-resistant schizophrenia (TRS) remains unclear. Previous neuroimaging studies suggest that aberrant connectivity between the anterior cingulate cortex (ACC) and default mode network (DMN) may play a key role in the pathophysiology of TRS. Thus, we aimed to examine the connectivity between the ACC and posterior cingulate cortex (PCC), a hub of the DMN, computing isolated effective coherence (iCoh), which represents causal effective connectivity. **Methods:** Resting-state electroencephalogram with 19 channels was acquired from seventeen patients with TRS and thirty patients with non-TRS (nTRS). The iCoh values between the PCC and ACC were calculated using sLORETA software. We conducted four-way analyses of variance (ANOVAs) for iCoh values with group as a between-subject factor and frequency, directionality, and laterality as within-subject factors and post-hoc independent *t*-tests. **Results:** The ANOVA and post-hoc *t*-tests for the iCoh ratio of directionality from PCC to ACC showed significant findings in delta ($t_{45} = 7.659, p = 0.008$) and theta ($t_{45} = 8.066, p = 0.007$) bands in the left side (TRS < nTRS). **Conclusion:** Left delta and theta PCC and ACC iCoh ratio may represent a neurophysiological basis of TRS. Given the preliminary nature of this study, these results warrant further study to confirm the importance of iCoh as a clinical indicator for treatment-resistance.

Keywords: treatment-resistant schizophrenia; causal effective connectivity; isolated effective coherence; resting-state electroencephalography; anterior cingulate cortex; posterior cingulate cortex; default mode network

1. Introduction

Approximately one-third of patients with schizophrenia do not respond to antipsychotic treatment [1,2], which is considered as treatment-resistant schizophrenia (TRS). As the quality of life in patients with TRS is remarkably disturbed through their lifespan, understanding the pathophysiology of TRS is a priority for mental health research. However, the neural basis of TRS, especially the difference from non-treatment resistant schizophrenia (nTRS), remains unclear [3].

One brain region commonly reported to show abnormal structural and functional findings in patients with schizophrenia is the anterior cingulate cortex (ACC) [4–6]. The ACC is an area crucial for integrating emotional, cognitive/attentional, and nociceptive functioning, as well as motor processing [7]. Additionally, previous proton magnetic resonance spectroscopy studies demonstrated that patients with TRS showed increased levels of glutamatergic neurometabolites in the ACC compared with patients with nTRS [8] or healthy controls [9–11]. Thus, while dysfunction of the ACC is among pathological neural bases for schizophrenia, it may also be related to that for TRS.

Several resting-state functional magnetic resonance imaging (fMRI) studies have shown that connectivity within the default mode network (DMN) is increased in patients with schizophrenia compared with healthy controls [12–14]. The DMN correlates closely with the resting-state human brain activity and is thought to be involved in the monitoring of internal processes as well as internal and external cognition [15]. A number of studies suggested that impaired DMN may be related to various types of symptoms such as cognitive impairment and psychotic symptoms and be associated with long-term clinical outcomes in patients with schizophrenia [16–18]. In addition, previous fMRI studies have indicated that connectivity between the posterior cingulate cortex (PCC), one of the core nodes of the DMN, and ACC is associated with both positive and negative symptoms in patients with schizophrenia [19–21]. Notably, Alonso-Solis et al. reported that patients with TRS demonstrated decreased functional connectivity between the PCC and ACC compared with patients with nTRS [22]. Moreover, patients with schizophrenia who had higher severity of hallucination or delusions demonstrated reduced fractional anisotropy values of the cingulum bundle, as measured by diffusion tensor tractography [23], as well as a reduced magnetization transfer ratio, as measured by MRI [24]. These findings suggest that both functional and structural aberrant connectivity between the ACC and DMN may play a key role in the pathophysiology of TRS.

A recent development in computational techniques has enabled non-invasive measurements of scalp electroencephalography (EEG) to estimate not only local activities at arbitrary brain regions, but also functional connectivities between any two brain regions. Recently, in particular, a new method has been developed to calculate effective directional connectivities called “isolated effective coherence (iCoh)” [25]. The iCoh is considered to represent one of the causal effective connectivities that can specifically estimate the directionality of information flow along a specific path. Most of the brain nodes not only directly, but also indirectly affect one another. Distinguishing between them leads to more precise information. Although it is difficult to do so, the partial directed coherence (PDC) can be used to quantify direct connections that are not confounded by indirect paths, their directionality, and their spectral characteristics. However, this method is influenced by the sender nodes of interest and may decrease in the presence of many nodes, even if the relationship between a sender and receiver node of a particular interest remains unchanged [26]. Here, the iCoh is a novel method that overcomes the abovementioned limitations by estimating the partial coherence under a multivariate autoregressive model. Of note, the better accuracy of the iCoh method has been confirmed by several studies compared with the PDC [25–27].

For further investigation of the pathophysiology of TRS, it is indispensable to detect the direction of abnormality between the ACC and DMN. In this study, we hypothesized that the aberrant effective connectivity between the PCC and ACC may be associated with the pathophysiology of TRS. Therefore, we aimed to investigate the causal effective connectivities as indexed by iCoh of resting-state EEG, focusing on the path between the PCC and ACC between patients with TRS and nTRS.

2. Materials and Methods

2.1. Participants

This study was approved by the ethics committees at Komagino Hospital (IRB code: 20160504) on 22 October 2016 and Keio University School of Medicine (IRB code: 20160320) on 23 July 2018. All participants were included following the completion of an informed consent procedure. All patients were recruited from Komagino Hospital, Tokyo, Japan and had a diagnosis of schizophrenia or schizoaffective disorder based on the Diagnostic and Statistical Manual of Mental Disorders IV. Seventeen patients with TRS and thirty patients with nTRS were enrolled in this study. Treatment-resistance to antipsychotics was defined by the modified treatment response and resistance in psychosis (TRRIP) working group consensus criteria [28]. Specifically, TRS criteria included a history of treatment failure to optimal treatment with at least two previous non-clozapine antipsychotics, while nTRS criteria included the following: (i) current intake of a non-clozapine single antipsychotic and (ii) treatment response: every positive and negative syndrome scale (PANSS) [29] positive score less than 3 points, and clinical global impression score less than 3 points. We excluded patients who had (i) substance abuse/dependence within the past 6 months; (ii) history of head trauma resulting in loss of consciousness for more than 30 min; (iii) serious or unstable physical illness; or (iv) current administration of lamotrigine, topiramate, or memantine.

2.2. Clinical Assessments

The severity of clinical symptoms was assessed with the PANSS by experienced qualified psychiatrists (R.T. and S.N.).

2.3. Measurement and Preprocessing of Resting-State EEG

Resting-state EEG was acquired for approximately 5 min with a 19-channel EEG system (Neurofax EEG-1214, Nihon Kohden, Inc., Tokyo, Japan) according to the 10–20 international system using a linked earlobes reference. Subjects were instructed to keep their eyes closed while staying awake during the EEG recording. EEG data were recorded at the sampling rate of 500 Hz and electrode impedances were kept below 5 k Ω during the recording. EEG data were band-pass filtered off-line at 0.1–100 Hz. Blink and eye-movement related artifacts were removed using independent component analysis. After removing the periods contaminated with noise with a visual inspection, EEG data were concatenated and preprocessed with R software (2018). Subsequently, preprocessed EEG data was processed using standardized low-resolution brain electromagnetic tomography, which is implemented within sLORETA software [25,30].

2.4. iCoh Analysis

In the present study, we calculated the causal effective connectivity as indexed with the iCoh using sLORETA software [25] among the various functional connectivity indices. The iCoh is defined by the formula based on a multivariate autoregressive model, calculating the corresponding partial coherences after setting all irrelevant connections to zero other than the particular directional paths of interest. Here, a multivariate autoregressive model is a mathematical model of two-time series data that can be estimated using a linear sum of the history of the two-time series data. The partial coherence is a measure of connection between two complex-valued random variables after removing the effect of other measured variables. Again, technical details are described in a previously published article [25]. Information on effective connectivity provided by the iCoh method is supposed to represent “direct” paths of connections between the pairs of regions, excluding the influence of indirect connection paths [25]. Furthermore, iCoh provides two-directional estimators for the strength of oscillatory information flow between each pair of regions such as from region “A” to “B” and from region “B” to “A” [31].

The primary analysis of causal effective connectivity as indexed by iCoh was performed for region of interest (ROI) pairs between the PCC and ACC individually for each group. Subsequently, connectivity for each frequency band (i.e., delta: 1.5–3 Hz, theta: 4–7 Hz, alpha: 8–13 Hz, beta: 14–30 Hz, low-gamma: 30–45 Hz, and high-gamma: 55–70 Hz) was calculated. The ROI names, abbreviations, and the Montreal Neurological Institute (MNI)-coordinates are listed in Supplemental Table S1.

2.5. Statistical Analysis

Statistical analyses were performed using the SPSS software (version 25, SPSS Inc., Chicago, IL, USA). Clinico-demographic characteristics, including age, sex, years of education, age of onset, treatment duration, chlorpromazine (CPZ), and PANSS total scores were compared between the groups by χ^2 -tests or independent *t*-tests for categorical or continuous variables, respectively. In this study, normal distributions of the iCoh data were confirmed with Shapiro–Wilk tests before performing the parametric statistical testing. The iCoh values were statistically analyzed by four-way repeated-measures analysis of variance (rm-ANOVA) using “group” (i.e., two groups: TRS and nTRS) as a between-subject factor and “frequency” (i.e., six frequency bands: delta, theta, alpha, beta, low-gamma, and high-gamma), “directionality” (two directions: e.g., PCC to ACC and ACC to PCC), and “laterality” (two lateralities: right and left) as within-subject factors. When significant differences were found in any interactions, subsequent post-hoc rm-ANOVAs (i.e., three-way and two-way ANOVAs) were conducted. Finally, we performed post-hoc independent *t*-tests for the ratio of bidirectionality of iCoh values. The ratio was calculated as follows: [(PCC to ACC) – (ACC to PCC)]/[(PCC to ACC) + (ACC to PCC)]. Here, the significance level of alpha was set as 0.05, however, only for post hoc analyses of four-way ANOVA, the alpha level was set as 0.01 depending on the number of frequency bands ($0.05/5 = 0.01$). Pearson’s correlation coefficients between chlorpromazine (CPZ) equivalent daily doses and iCoh values were calculated in order to check the effect of antipsychotics on the iCoh as a confounding factor.

In addition, Pearson’s correlation coefficients were calculated for the results showing significant findings in the above ANOVA model to examine the correlations among iCoh values within the ROIs and clinical symptoms as assessed with the PANSS total scores.

Moreover, we conducted a receiver operating characteristic (ROC) analysis to investigate the sensitivity and specificity of the iCoh index in discriminating between TRS and nTRS.

3. Results

3.1. Clinico-Demographics Data

Clinico-demographic data are summarized in Table 1. There were no significant group differences in age, sex, years of education, age of onset, and treatment duration other than CPZ equivalent daily doses and PANSS total scores, suggesting the nature of differences between TRS and nTRS.

Table 1. Clinico-demographics data.

	nTRS (n = 30)	TRS (n = 17)	<i>t</i> -Value (Chi-Squared Value for Sex), <i>p</i> -Value
Age, mean (SD), years	41.2 (12.6)	42.4 (13.4)	$t_{45} = 0.29, p = 0.78$
Sex (number of male) (%)	13 (43)	5 (29)	$\chi^2_{45} = 0.89, p = 0.34$
Education, mean (SD), years	13.3 (1.81)	13.3 (2.42)	$t_{45} = 0.06, p = 0.95$
Age of onset, mean (SD), years	26.0 (9.47)	26.6 (7.64)	$t_{45} = 0.23, p = 0.82$
Treatment duration, mean (SD), years	14.5 (12.0)	15.5 (11.3)	$t_{45} = 0.27, p = 0.79$
Chlorpromazine equivalents, mean (SD), mg	406 (233.5)	748 (319.0)	$t_{45} = 4.22, p < 0.001 *$
PANSS total, mean (SD)	48.8 (12.7)	114.6 (21.2)	$t_{45} = 13.4, p < 0.001 *$

TRS: treatment-resistant schizophrenia; nTRS: non treatment-resistant schizophrenia; SD: standard deviation; PANSS: positive and negative syndrome scale, * = $p < 0.05$.

3.2. Four-Way ANOVA for iCoh Values

Four-way ANOVAs for iCoh values between the PCC and ACC indicated the following results. There was a significant group \times frequency \times directionality \times laterality interaction for iCoh values between the PCC and ACC connectivity among the four-way ANOVAs. Consequently, post-hoc independent t -tests for the iCoh ratio of directionality from PCC to ACC showed significant findings that the ratio was decreased in TRS compared with nTRS in delta ($t_{45} = 7.659$, $p = 0.008$; alpha = 0.01) and theta ($t_{45} = 8.066$, $p = 0.007$; alpha = 0.01) frequency bands in the left side (Figure 1). The results of ANOVAs and post-hoc independent t -tests are summarized in Supplemental Table S2.




Figure 1. Schematics of the causal effective connectivity between the posterior cingulate cortex (PCC) and anterior cingulate cortex (ACC). In patients with treatment-resistant schizophrenia (TRS), the isolated effective coherence (iCoh) ratios $[(PCC \text{ to } ACC) - (ACC \text{ to } PCC)] / [(PCC \text{ to } ACC) + (ACC \text{ to } PCC)]$ in delta and theta bands over the left side were significantly decreased compared with patients with non-TRS (nTRS).

Of note, there were no significant correlations between CPZ equivalent daily doses and iCoh values in either TRS group ($r = -0.196$, $p = 0.225$) or nTRS group ($r = 0.064$, $p = 0.368$).

3.3. Clinical Correlation with iCoh

Pearson's correlational analyses indicated a trend toward a significant correlation between the iCoh ratio for the left delta PCC–ACC connectivity and PANSS total score only for TRS group ($r = 0.38$, $p = 0.069$), but not for nTRS group ($r = -0.18$, $p = 0.17$) (Figure 2).

3.4. ROC Analysis of the iCoh Ratio between TRS and nTRS

Regarding the discrimination between TRS and nTRS groups, the ROC analysis that employed the iCoh ratio for the left delta PCC–ACC connectivity showed a significant asymptotic p -value ($p = 0.023$; confidence interval: 0.536–0.868) with an area under the curve of 0.70. Further, the sensitivity and specificity at the optimum point of the ROC curve were 0.64 and 0.70, respectively.

may induce severity of symptoms or global impairment of cognitive function [45–47]. For example, a smaller volume of the ACC is significantly correlated with more severe positive symptoms of schizophrenia [45] and related to global cognitive impairment measured by the Brief Assessment of Cognition in Schizophrenia [47]. Notably, previous studies noted that patients with TRS had elevated levels of glutamatergic neurometabolites in the ACC [9–11]. These findings suggest that our results may explain the features of TRS including more severe positive symptoms, poorer cognitive function, and social function compared with nTRS. Additionally, impaired functional communication between the two regions might make them worse reciprocally. However, the ROC analysis using the iCoh ratio demonstrated a moderate accuracy to differentiate between patients with TRS and nTRS. While the iCoh ratio between the PCC and ACC may be a potential biomarker to distinguish between the two groups, future work is needed to disentangle the pathophysiology of TRS with a combination of multimodal biological measures.

Several studies have shown that the left cingulum is more related to positive symptoms of schizophrenia compared with the right cingulum. Reduced extracellular free-water as measured by diffusion MRI in the left cingulum was associated with delusions in patients with schizophrenia [48]. In addition, Palaniyappan et al. demonstrated that a reduced magnetization transfer ratio in the left cingulum was associated with a higher severity of delusions, while no such relationship was observed in the right cingulum [24]. Collectively, both functional and structural connectivities between the left PCC and ACC may be related to the severity of symptoms as represented by delusions. Additionally, Yuan et al. revealed that patients with schizophrenia who had never been treated for a long term showed more severe white matter abnormalities in the left cingulum-hippocampus pathway compared with patients with schizophrenia who had been treated [49]. This finding supports our hypothesis that the persistent symptoms observed in patients with TRS may be associated with functional abnormalities in the left cingulate cortex. Thus, these findings are in line with our result that the reduction of iCoh ratio was present only in the left side.

Unlike the neuroimaging studies, EEG enables the assessment of cortical network dynamics because of the high temporal resolution. Delta band oscillations are linked with learning, memory encoding and retrieval, and motivation and reward processes [50,51]. The activity of theta band oscillations has been linked to working memory, emotional arousal, and fear conditioning [51]. For example, Hlinka et al. reported that, in an inter-subject experimental design, a strong relationship was established between functional connectivity in delta band oscillations and the DMN [52]. Furthermore, Neuner et al. demonstrated a highly significant correlation between delta band oscillation and spontaneous blood-oxygen-level dependent (BOLD) signal within the DMN using simultaneous fMRI–EEG study [53]. Thus, delta band oscillations may represent the normal functioning of the DMN.

Our findings also suggest a new treatment option for TRS such as neuromodulation. Specifically, non-invasive novel neurostimulation techniques including transcranial magnetic stimulation (TMS) and deep brain stimulation (DBS) enable us to modulate the local neural connectivity [54,55]. Thus, the abnormal neural connectivity in the cingulate bundle can be one of the therapeutic targets. Given the limited treatment options for TRS, neurostimulation targeting the pathological neural basis as described above may be a promising therapeutic strategy.

There are several limitations to the present study. First, we did not include a healthy control group. Comparison between patients with schizophrenia and health control group may reveal comprehensive dysfunction in patients with schizophrenia, which will help to clarify the position of our current findings. Second, we did not include the potential covariates in the statistical analyses such as the dose of antipsychotics as indexed with CPZ equivalent daily doses. However, we did not see a correlation between the dose of antipsychotics and iCoh values or clinical severity. Third, the present study included relatively small sample sizes in both subdiagnostic groups (i.e., TRS and nTRS). Owing to Coronavirus disease 2019 (COVID-19), we could not continue to enroll subjects at this stage. Therefore, our findings warrant further studies with larger sample sizes in this illness using the TRRIP working group consensus criteria [28]. Fourth, we focused only on the effective connectivity between the ACC

and PCC as a hypothesis-based manner; however, there may be other potential network abnormalities in patients with schizophrenia. Further research is needed using multimodal imaging based on multifaceted perspectives. Fifth, we have only assessed psychiatric symptoms using the PANSS. Thus, there were no clinical measures for other symptoms like depression or anxiety. As schizophrenia is a multifaceted disorder, future research needs to include a variety of clinical measures. Lastly, in this study, we used the standard 10–20 EEG system using 19 electrodes, which could lead to incorrect localization. Because the number of source-level electrodes in the present study was small, we may not have been able to accurately estimate the source of the deep brain signals. Therefore, the present preliminary analyses warrant further studies to confirm the reproducibility and reliability of these results by, for example, using a higher resolution EEG system with 64 channel electrodes and combining them with more sophisticated signal source analysis techniques. However, several previous studies have performed the sLORETA analysis on 19-electrode EEGs [56–59].

5. Conclusions

In conclusion, we found significant differences in the iCoh ratio between the left PCC and ACC in delta and theta bands between patients with TRS and nTRS. Taken together, these findings may represent part of the underlying neural basis of TRS. The present findings warrant further research in larger sample sizes with multimodal examinations to elucidate underlying mechanisms of treatment-resistance in this illness.

Supplementary Materials: The following are available online at <http://www.mdpi.com/2075-4426/10/3/89/s1>. Table S1: MNI coordinates, Table S2: Summary of significant results of 4-way ANOVA.

Author Contributions: Conceptualization, Y.N.; methodology, Y.N. and T.M.; software, F.M.; validation, M.W.; formal analysis, M.W. and Y.N.; data curation, T.M., S.H., K.M., and Y.K.; writing: original draft preparation, M.W., F.M., and Y.N.; manuscript editing, Y.N., S.T., K.O., S.F., D.M.B., and Z.J.D.; visualization, M.W.; supervision, Y.N. and S.N.; project administration, R.T., S.H., K.M., Y.K., and S.N.; funding acquisition, S.N., M.M., and Y.N. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the Japan Society for the Promotion of Science and AMED to Y.N., S.N., and M.M. The funding agency did not contribute to the study design; in the data collection, analyses, and interpretation; in the writing of the manuscript; and in the decision to submit the manuscript for publication.

Acknowledgments: We thank Nishikata for his technical support. Furthermore, we appreciate all the patients who have participated in this study.

Conflicts of Interest: M.W., R.T., F.M., T.M., S.T., K.O., S.H., K.M., and Y.K. report no biomedical interests. S.N. has received fellowship grants from CIHR, Japan Research Foundation for Clinical Pharmacology, Naito Foundation, Takeda Science Foundation, Uehara Memorial Foundation, and Daiichi Sankyo Scholarship Donation Program within the past three years. S.N. has also received research supports, manuscript fees, or speaker's honoraria from Dainippon Sumitomo Pharma, Meiji-Seika Pharma, Otsuka Pharmaceutical, Shionogi, and Yoshitomi Yakuhin within the past three years. Z.J.D. has received research and equipment in-kind support for an investigator-initiated study through Brainsway Inc and Magventure Inc. His work was supported by the Ontario Mental Health Foundation (OMHF), the Canadian Institutes of Health Research (CIHR), the National Institutes of Mental Health (NIMH), and the Temerty Family and Grant Family and through the Centre for Addiction and Mental Health (CAMH) Foundation and the Campbell Institute. M.M. has received research support from Japan Society for the Promotion of Science and grants or speaker's honoraria from Daiichi Sankyo, Dainippon-Sumitomo Pharma, Eisai, Eli Lilly, Fuji Film RI Pharma, Janssen Pharmaceutical, Mochida Pharmaceutical, M.S.D., Nippon Chemipher, Novartis Pharma, Ono Yakuhin, Otsuka Pharmaceutical, Pfizer, Takeda Yakuhin, Tsumura, and Yoshitomi Yakuhin within the past three years. D.M.B. receives research support from the Canadian Institutes of Health Research (CIHR), National Institutes of Health—US (NIH), Weston Brain Institute, Brain Canada, and the Temerty Family through the CAMH Foundation and the Campbell Research Institute. He received research support and in-kind equipment support for an investigator-initiated study from Brainsway Ltd. and he is the site principal investigator for three sponsor-initiated studies for Brainsway Ltd. He received in-kind equipment support from Magventure for an investigator-initiated study. He received medication supplies for an investigator-initiated trial from Indivior. He has participated in an advisory board for Janssen. Y.N. has received a Grant-in-Aid for Young Scientists (KAKENHI), a research grant from Japan Agency for Medical Research and development (AMED), an investigator-initiated clinical study grant from TEIJIN PHARMA LIMITED. Y.N. also received research grants from Japan Health Foundation, Meiji Yasuda Mental Health Foundation, Mitsui Life Social Welfare Foundation, Takeda Science Foundation, SENSHIN Medical Research Foundation, Health Science Center Foundation, Mochida Memorial Foundation for Medical and Pharmaceutical Research, and Daiichi Sankyo Scholarship Donation Program. He has received research supports from Otsuka Pharmaceutical, Shionogi, and Meiji Seika Pharma. Y.N.

also received equipment-in-kind supports for an investigator-initiated study from Magventure Inc., Inter Reha Co., Ltd., Rogue Resolutions Ltd., and Miyuki Giken Co., Ltd.

Abbreviations

ACC	anterior cingulate cortex
CPZ	chlorpromazine
DMN	default mode network
DBS	deep brain stimulation
EEG	electroencephalography
fMRI	functional magnetic resonance imaging
iCoh	isolated effective coherence
IPL	inferior parietal lobe
ITL	inferior temporal lobe
mPFC	medial prefrontal cortex
MNI	Montreal Neurological Institute
PANSS	positive and negative syndrome scale
PCC	posterior cingulate cortex
rm-ANOVA	repeated-measures analysis of variance
ROC	receiver operating characteristic
ROIs	regions of interest
sLORETA	standardized low-resolution brain electromagnetic tomography
TRRIP	treatment response and resistance in psychosis
TMS	transcranial magnetic stimulation
TRS	treatment-resistant schizophrenia
nTRS	non treatment-resistant schizophrenia

References

- Hasan, A.; Falkai, P.; Wobrock, T.; Lieberman, J.; Glenthøj, B.; Gattaz, W.F.; Thibaut, F.; Möller, H.-J. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. *World J. Biol. Psychiatry* **2012**, *13*, 318–378. [[CrossRef](#)] [[PubMed](#)]
- Samara, M.T.; Dold, M.; Gianatsi, M.; Nikolakopoulou, A.; Helfer, B.; Salanti, G.; Leucht, S. Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A network meta-analysis. *JAMA Psychiatry* **2016**, *73*, 199. [[CrossRef](#)]
- Nakajima, S.; Takeuchi, H.; Plitman, E.; Fervaha, G.; Gerretsen, P.; Caravaggio, F.; Chung, J.K.; Iwata, Y.; Remington, G.; Graff-Guerrero, A. Neuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophrenia. *Schizophr. Res.* **2015**, *164*, 164–175. [[CrossRef](#)] [[PubMed](#)]
- Carter, C.S.; Macdonald, A.; Ross, L.L.; Stenger, V.A. Anterior Cingulate Cortex Activity and Impaired Self-Monitoring of Performance in Patients with Schizophrenia: An Event-Related fMRI Study. *Am. J. Psychiatry* **2001**, *158*, 1423–1428. [[CrossRef](#)]
- Walter, H.; Ciaramidaro, A.; Adenzato, M.; Vasic, N.; Ardito, R.B.; Erk, S.; Bara, B.G. Dysfunction of the social brain in schizophrenia is modulated by intention type: An fMRI study. *Soc. Cogn. Affect. Neurosci.* **2009**, *4*, 166–176. [[CrossRef](#)] [[PubMed](#)]
- Yan, H.; Tian, L.; Yan, J.; Sun, W.; Liu, Q.; Zhang, Y.-B.; Li, X.-M.; Zang, Y.-F.; Zhang, D. Functional and Anatomical Connectivity Abnormalities in Cognitive Division of Anterior Cingulate Cortex in Schizophrenia. *PLoS ONE* **2012**, *7*, e45659. [[CrossRef](#)]
- Salgado-Pineda, P.; Landin-Romero, R.; Fakra, E.; Delaveau, P.; Amann, B.L.; Blin, O. Structural Abnormalities in Schizophrenia: Further Evidence on the Key Role of the Anterior Cingulate Cortex. *Neuropsychobiology* **2014**, *69*, 52–58. [[CrossRef](#)]

8. Mouchlianitis, E.; Bloomfield, M.A.P.; Law, V.; Beck, K.; Selvaraj, S.; Rasquinha, N.; Waldman, A.D.; Turkheimer, F.E.; Egerton, A.; Stone, J.; et al. Treatment-Resistant Schizophrenia Patients Show Elevated Anterior Cingulate Cortex Glutamate Compared to Treatment-Responsive. *Schizophr. Bull.* **2015**, *42*, 744–752. [[CrossRef](#)]
9. Iwata, Y.; Nakajima, S.; Plitman, E.; Caravaggio, F.; Kim, J.; Shah, P.; Mar, W.; Chavez, S.; De Luca, V.; Mimura, M.; et al. Glutamatergic Neurometabolite Levels in Patients With Ultra-Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton Magnetic Resonance Spectroscopy Study. *Biol. Psychiatry* **2019**, *85*, 596–605. [[CrossRef](#)]
10. Demjaha, A.; Egerton, A.; Murray, R.M.; Kapur, S.; Howes, O.D.; Stone, J.; McGuire, P. Antipsychotic Treatment Resistance in Schizophrenia Associated with Elevated Glutamate Levels but Normal Dopamine Function. *Boil. Psychiatry* **2014**, *75*, e11–e13. [[CrossRef](#)]
11. Tarumi, R.; Tsugawa, S.; Noda, Y.; Plitman, E.; Honda, S.; Matshusita, K.; Chavez, S.; Sawada, K.; Wada, M.; Matsui, M.; et al. Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: A proton magnetic resonance spectroscopy study. *Neuropsychopharmacology* **2020**, *46*, S313. [[CrossRef](#)] [[PubMed](#)]
12. Jafri, M.J.; Pearlson, G.D.; Stevens, M.C.; Calhoun, V.D. A method for functional network connectivity among spatially independent resting-state components in schizophrenia. *NeuroImage* **2008**, *39*, 1666–1681. [[CrossRef](#)] [[PubMed](#)]
13. Skudlarski, P.; Jagannathan, K.; Anderson, K.; Stevens, M.C.; Calhoun, V.D.; Skudlarska, B.A.; Pearlson, G. Brain Connectivity Is Not Only Lower but Different in Schizophrenia: A Combined Anatomical and Functional Approach. *Biol. Psychiatry* **2010**, *68*, 61–69. [[CrossRef](#)] [[PubMed](#)]
14. Zhou, C.; Yu, M.; Tang, X.; Wang, X.; Zhang, X.; Zhang, X.R.; Chen, J. Convergent and divergent altered patterns of default mode network in deficit and non-deficit schizophrenia. *Prog. Neuro Psychopharmacol. Biol. Psychiatry* **2019**, *89*, 427–434. [[CrossRef](#)] [[PubMed](#)]
15. Buckner, R.L.; Schacter, D.L.; Andrews-Hanna, J.R. The Brain’s Default Network. *Ann. N. Y. Acad. Sci.* **2008**, *1124*, 1–38. [[CrossRef](#)] [[PubMed](#)]
16. Krukow, P.; Jonak, K.; Grochowski, C.; Plechawska-Wójcik, M.; Karakuła-Juchnowicz, H. Resting-state hyperconnectivity within the default mode network impedes the ability to initiate cognitive performance in first-episode schizophrenia patients. *Prog. Neuro Psychopharmacol. Biol. Psychiatry* **2020**, *102*, 109959. [[CrossRef](#)]
17. Lee, H.; Lee, D.-K.; Park, K.; Kim, C.-E.; Ryu, S. Default mode network connectivity is associated with long-term clinical outcome in patients with schizophrenia. *NeuroImage Clin.* **2019**, *22*, 101805. [[CrossRef](#)] [[PubMed](#)]
18. Fox, J.M.; Abram, S.V.; Reilly, J.L.; Eack, S.; Goldman, M.B.; Csernansky, J.G.; Wang, L.; Smith, M.J. Default mode functional connectivity is associated with social functioning in schizophrenia. *J. Abnorm. Psychol.* **2017**, *126*, 392–405. [[CrossRef](#)] [[PubMed](#)]
19. Bluhm, R.L.; Miller, J.; Lanius, R.A.; Osuch, E.A.; Boksman, K.; Neufeld, R.; Théberge, J.; Schaefer, B.; Williamson, P. Spontaneous Low-Frequency Fluctuations in the BOLD Signal in Schizophrenic Patients: Anomalies in the Default Network. *Schizophr. Bull.* **2007**, *33*, 1004–1012. [[CrossRef](#)]
20. Garrity, A.G.; Pearlson, G.D.; McKiernan, K.; Lloyd, D.; Kiehl, K.A.; Calhoun, V.D. Aberrant “default mode” functional connectivity in schizophrenia. *Am. J. Psychiatry* **2007**, *164*, 450–457. [[CrossRef](#)]
21. Hare, S.M.; Ford, J.M.; Mathalon, D.H.; Damaraju, E.; Bustillo, J.; Belger, A.; Lee, H.J.; A Mueller, B.; O Lim, K.; Brown, G.G.; et al. Salience–Default Mode Functional Network Connectivity Linked to Positive and Negative Symptoms of Schizophrenia. *Schizophr. Bull.* **2018**, *45*, 892–901. [[CrossRef](#)] [[PubMed](#)]
22. Alonso-Solís, A.; Vives-Gilabert, Y.; Grasa, E.; Portella, M.J.; Rabella, M.; Sauras, R.B.; Roldán, A.; Núñez-Marín, F.; Gomez-Anson, B.; Pérez, V.; et al. Resting-state functional connectivity alterations in the default network of schizophrenia patients with persistent auditory verbal hallucinations. *Schizophr. Res.* **2015**, *161*, 261–268. [[CrossRef](#)] [[PubMed](#)]
23. Whitford, T.J.; Lee, S.W.; Oh, J.S.; De Luis-García, R.; Savadjiev, P.; Alvarado, J.L.; Westin, C.-F.; Niznikiewicz, M.; Nestor, P.G.; McCarley, R.W.; et al. Localized abnormalities in the cingulum bundle in patients with schizophrenia: A Diffusion Tensor tractography study. *NeuroImage Clin.* **2014**, *5*, 93–99. [[CrossRef](#)] [[PubMed](#)]

24. Palaniyappan, L.; Al-Radaideh, A.; Mouglin, O.; Das, T.; Gowland, P.A.; Liddle, P.F. Aberrant myelination of the cingulum and Schneiderian delusions in schizophrenia: A 7T magnetization transfer study. *Psychol. Med.* **2018**, *49*, 1890–1896. [[CrossRef](#)]
25. Pascual-Marqui, R.D.; Biscay, R.J.; Bosch-Bayard, J.; Lehmann, D.; Kochi, K.; Kinoshita, T.; Yamada, N.; Sadato, N. Assessing direct paths of intracortical causal information flow of oscillatory activity with the isolated effective coherence (iCoh). *Front. Hum. Neurosci.* **2014**, *8*, 448. [[CrossRef](#)]
26. Schelter, B.; Timmer, J.; Eichler, M. Assessing the strength of directed influences among neural signals using renormalized partial directed coherence. *J. Neurosci. Methods* **2009**, *179*, 121–130. [[CrossRef](#)] [[PubMed](#)]
27. Plomp, G.; Quairiaux, C.; Michel, C.M.; Astolfi, L. The physiological plausibility of time-varying Granger-causal modeling: Normalization and weighting by spectral power. *NeuroImage* **2014**, *97*, 206–216. [[CrossRef](#)]
28. Howes, O.D.; McCutcheon, R.A.; Agid, O.; De Bartolomeis, A.; Van Beveren, N.J.; Birnbaum, M.L.; Bloomfield, M.A.P.; Bressan, R.A.; Buchanan, R.W.; Carpenter, W.T.; et al. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. *Am. J. Psychiatry* **2017**, *174*, 216–229. [[CrossRef](#)]
29. Kay, S.R.; Fiszbein, A.; Opler, L.A. The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. *Schizophr. Bull.* **1987**, *13*, 261–276. [[CrossRef](#)]
30. Pascual-Marqui, R.D.; Michel, C.; Lehmann, D. Low resolution electromagnetic tomography: A new method for localizing electrical activity in the brain. *Int. J. Psychophysiol.* **1994**, *18*, 49–65. [[CrossRef](#)]
31. Kitaura, Y.; Nishida, K.; Yoshimura, M.; Mii, H.; Katsura, K.; Ueda, S.; Ikeda, S.; Pascual-Marqui, R.D.; Ishii, R.; Kinoshita, T. Functional localization and effective connectivity of cortical theta and alpha oscillatory activity during an attention task. *Clin. Neurophysiol. Pr.* **2017**, *2*, 193–200. [[CrossRef](#)] [[PubMed](#)]
32. Mouchlianitis, E.; McCutcheon, R.A.; Howes, O.D. Brain-imaging studies of treatment-resistant schizophrenia: A systematic review. *Lancet Psychiatry* **2016**, *3*, 451–463. [[CrossRef](#)]
33. Coito, A.; Michel, C.M.; Vulliemoz, S.; Plomp, G. Directed functional connections underlying spontaneous brain activity. *Hum. Brain Mapp.* **2019**, *40*, 879–888. [[CrossRef](#)] [[PubMed](#)]
34. Fransson, P.; Marrelec, G. The precuneus/posterior cingulate cortex plays a pivotal role in the default mode network: Evidence from a partial correlation network analysis. *NeuroImage* **2008**, *42*, 1178–1184. [[CrossRef](#)]
35. Tao, Y.; Liu, B.; Zhang, X.; Li, J.; Qin, W.; Yu, C.; Jiang, T. The Structural Connectivity Pattern of the Default Mode Network and Its Association with Memory and Anxiety. *Front. Neuroanat.* **2015**, *9*, 152. [[CrossRef](#)]
36. Maddock, R.J.; Garrett, A.S.; Buonocore, M.H. Remembering familiar people: The posterior cingulate cortex and autobiographical memory retrieval. *Neuroscience* **2001**, *104*, 667–676. [[CrossRef](#)]
37. Lefebvre, S.; Demeulemeester, M.; Leroy, A.; Delmaire, C.; Lopes, R.; Pins, D.; Thomas, P.; Jardri, R. Network dynamics during the different stages of hallucinations in schizophrenia. *Hum. Brain Mapp.* **2016**, *37*, 2571–2586. [[CrossRef](#)]
38. Manoliu, A.; Riedl, V.; Zherdin, A.; Mühlau, M.; Schwerthöffer, D.; Scherr, M.; Peters, H.; Zimmer, C.; Förstl, H.; Bäuml, J.; et al. Aberrant dependence of default mode/central executive network interactions on anterior insular salience network activity in schizophrenia. *Schizophr. Bull.* **2014**, *40*, 428–437. [[CrossRef](#)]
39. Lagioia, A.; Van De Ville, D.; Debbané, M.; Lazeyras, F.; Eliez, S. Adolescent resting state networks and their associations with schizotypal trait expression. *Front. Syst. Neurosci.* **2010**, *4*, 4. [[CrossRef](#)]
40. Tettamanti, M.; Vaghi, M.M.; Bara, B.G.; Cappa, S.F.; Enrici, I.; Adenzato, M. Effective connectivity gateways to the Theory of Mind network in processing communicative intention. *NeuroImage* **2017**, *155*, 169–176. [[CrossRef](#)]
41. Quidé, Y.; Wilhelmi, C.; Green, M.J. Structural brain morphometry associated with theory of mind in bipolar disorder and schizophrenia. *PsyCh J.* **2020**, *9*, 234–246. [[CrossRef](#)]
42. Corcoran, R.; Mercer, G.; Frith, C.D. Schizophrenia, symptomatology and social inference: Investigating “theory of mind” in people with schizophrenia. *Schizophr. Res.* **1995**, *17*, 5–13. [[CrossRef](#)]
43. Hakamata, Y.; Iwase, M.; Kato, T.; Senda, K.; Inada, T. The Neural Correlates of Mindful Awareness: A Possible Buffering Effect on Anxiety-Related Reduction in Subgenual Anterior Cingulate Cortex Activity. *PLoS ONE* **2013**, *8*, e75526. [[CrossRef](#)] [[PubMed](#)]
44. Wu, D.; Deng, H.; Xiao, X.; Zuo, Y.; Sun, J.; Wang, Z. Persistent Neuronal Activity in Anterior Cingulate Cortex Correlates with Sustained Attention in Rats Regardless of Sensory Modality. *Sci. Rep.* **2017**, *7*, 43101. [[CrossRef](#)] [[PubMed](#)]

45. Choi, J.-S.; Kang, D.-H.; Kim, J.-J.; Ha, T.-H.; Roh, K.S.; Youn, T.; Kwon, J.S. Decreased caudal anterior cingulate gyrus volume and positive symptoms in schizophrenia. *Psychiatry Res. Neuroimaging* **2005**, *139*, 239–247. [[CrossRef](#)] [[PubMed](#)]
46. Nelson, B.D.; Bjorkquist, O.A.; Olsen, E.K.; Herbener, E.S. Schizophrenia symptom and functional correlates of anterior cingulate cortex activation to emotion stimuli: An fMRI investigation. *Psychiatry Res.* **2015**, *234*, 285–291. [[CrossRef](#)]
47. Ohi, K.; Shimada, T.; Nemoto, K.; Kataoka, Y.; Yasuyama, T.; Kimura, K.; Okubo, H.; Uehara, T.; Kawasaki, Y. Cognitive clustering in schizophrenia patients, their first-degree relatives and healthy subjects is associated with anterior cingulate cortex volume. *NeuroImage Clin.* **2017**, *16*, 248–256. [[CrossRef](#)]
48. Oestreich, L.K.; Pasternak, O.; Shenton, M.E.; Kubicki, M.; Gong, X.; Whitford, T.J.; Australian Schizophrenia Research Bank; McCarthy-Jones, S.; Whitford, T.J. Abnormal white matter microstructure and increased extracellular free-water in the cingulum bundle associated with delusions in chronic schizophrenia. *NeuroImage Clin.* **2016**, *12*, 405–414. [[CrossRef](#)]
49. Xiao, Y.; Sun, H.; Shi, S.; Jiang, D.; Tao, B.; Zhao, Y.; Zhang, W.; Gong, Q.; Sweeney, J.A.; Lui, S. White Matter Abnormalities in Never-Treated Patients With Long-Term Schizophrenia. *Am. J. Psychiatry* **2018**, *175*, 1129–1136. [[CrossRef](#)]
50. Ekstrom, A.; Watrous, A.J. Multifaceted roles for low-frequency oscillations in bottom-up and top-down processing during navigation and memory. *NeuroImage* **2014**, *85*, 667–677. [[CrossRef](#)]
51. Knyazev, G.G. Motivation, emotion, and their inhibitory control mirrored in brain oscillations. *Neurosci. Biobehav. Rev.* **2007**, *31*, 377–395. [[CrossRef](#)] [[PubMed](#)]
52. Hlinka, J.; Alexakis, C.; Diukova, A.; Liddle, P.F.; Auer, D.P. Slow EEG pattern predicts reduced intrinsic functional connectivity in the default mode network: An inter-subject analysis. *NeuroImage* **2010**, *53*, 239–246. [[CrossRef](#)] [[PubMed](#)]
53. Neuner, I.; Arrubla, J.; Werner, C.J.; Hitz, K.; Boers, F.; Kawohl, W.; Shah, N.J. The Default Mode Network and EEG Regional Spectral Power: A Simultaneous fMRI-EEG Study. *PLoS ONE* **2014**, *9*, e88214. [[CrossRef](#)] [[PubMed](#)]
54. Tik, M.; Hoffmann, A.; Sladky, R.; Tomova, L.; Hummer, A.; De Lara, L.I.N.; Bukowski, H.; Pripfl, J.; Biswal, B.B.; Lamm, C.; et al. Towards understanding rTMS mechanism of action: Stimulation of the DLPFC causes network-specific increase in functional connectivity. *Neuroimage* **2017**, *162*, 289–296. [[CrossRef](#)]
55. Chiken, S.; Nambu, A. Mechanism of Deep Brain Stimulation: Inhibition, Excitation, or Disruption? *Neuroscientist* **2016**, *22*, 313–322. [[CrossRef](#)]
56. Lehmann, D.; Faber, P.L.; Tei, S.; Pascual-Marqui, R.D.; Milz, P.; Kochi, K. Reduced functional connectivity between cortical sources in five meditation traditions detected with lagged coherence using EEG tomography. *NeuroImage* **2012**, *60*, 1574–1586. [[CrossRef](#)]
57. A Ponomarev, V.; Kropotov, I.D. Improving source localization of ERPs in the GO/NOGO task by modeling of their cross-covariance structure. *Fiziol. Cheloveka* **2013**, *39*, 36–50.
58. Coben, R.; Hammond, D.C.; Arns, M. 19 Channel Z-Score and LORETA Neurofeedback: Does the Evidence Support the Hype? *Appl. Psychophysiol. Biofeedback* **2019**, *44*, 1–8. [[CrossRef](#)]
59. Eugene, A.R.; Masiak, J. Identifying Treatment Response of Sertraline in a Teenager with Selective Mutism using Electrophysiological Neuroimaging. *Int. J. Clin. Pharmacol. Toxicol.* **2016**, *5*, 216–219. [[CrossRef](#)]

